Expensive blood safety initiatives may offer less benefit than we think

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Expensive blood safety initiatives may offer less benefit than we think. / Kamper-Jørgensen, Mads; Hjalgrim, Henrik; Edgren, Gustaf; Titlestad, Kjell; Ullum, Henrik; Shanwell, Agneta; Reilly, Marie; Melbye, Mads; Nyrén, Olof; Rostgaard, Klaus.

In: Transfusion, Vol. 50, No. 1, 01.2010, p. 240-2.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Kamper-Jørgensen, M, Hjalgrim, H, Edgren, G, Titlestad, K, Ullum, H, Shanwell, A, Reilly, M, Melbye, M, Nyrén, O & Rostgaard, K 2010, 'Expensive blood safety initiatives may offer less benefit than we think', Transfusion, vol. 50, no. 1, pp. 240-2. https://doi.org/10.1111/j.1537-2995.2009.02374.x

APA

Kamper-Jørgensen, M., Hjalgrim, H., Edgren, G., Titlestad, K., Ullum, H., Shanwell, A., ... Rostgaard, K. (2010). Expensive blood safety initiatives may offer less benefit than we think. Transfusion, 50(1), 240-2. https://doi.org/10.1111/j.1537-2995.2009.02374.x

Vancouver

Kamper-Jørgensen M, Hjalgrim H, Edgren G, Titlestad K, Ullum H, Shanwell A et al. Expensive blood safety initiatives may offer less benefit than we think. Transfusion. 2010 Jan;50(1):240-2. https://doi.org/10.1111/j.1537-2995.2009.02374.x

Author

Kamper-Jørgensen, Mads ; Hjalgrim, Henrik ; Edgren, Gustaf ; Titlestad, Kjell ; Ullum, Henrik ; Shanwell, Agneta ; Reilly, Marie ; Melbye, Mads ; Nyrén, Olof ; Rostgaard, Klaus. / Expensive blood safety initiatives may offer less benefit than we think. In: Transfusion. 2010 ; Vol. 50, No. 1. pp. 240-2.

Bibtex

@article{2b2b0fcd2bd242a9a282cccb2375dc6b,
title = "Expensive blood safety initiatives may offer less benefit than we think",
abstract = "Various blood safety initiatives have ensured a historically low risk of infection transmission through blood transfusion. Although further prevention of infection transmission is possible through, for example, nucleic acid testing and future introduction of pathogen inactivation, such initiatives are very costly in relation to the benefit they offer. Although estimation of the cost-effectiveness requires detailed information about the survival of transfusion recipients, previous cost-effectiveness analyses have relied on incorrect survival assumptions.",
keywords = "Blood Banks, Blood Transfusion, Cost-Benefit Analysis, Follow-Up Studies, Humans, Infection, Infection Control, Quality of Health Care, Quality-Adjusted Life Years, Risk Factors, Scandinavia, Survival Analysis",
author = "Mads Kamper-J{\o}rgensen and Henrik Hjalgrim and Gustaf Edgren and Kjell Titlestad and Henrik Ullum and Agneta Shanwell and Marie Reilly and Mads Melbye and Olof Nyr{\'e}n and Klaus Rostgaard",
year = "2010",
month = "1",
doi = "10.1111/j.1537-2995.2009.02374.x",
language = "English",
volume = "50",
pages = "240--2",
journal = "Transfusion",
issn = "0041-1132",
publisher = "Wiley-Blackwell",
number = "1",

}

RIS

TY - JOUR

T1 - Expensive blood safety initiatives may offer less benefit than we think

AU - Kamper-Jørgensen, Mads

AU - Hjalgrim, Henrik

AU - Edgren, Gustaf

AU - Titlestad, Kjell

AU - Ullum, Henrik

AU - Shanwell, Agneta

AU - Reilly, Marie

AU - Melbye, Mads

AU - Nyrén, Olof

AU - Rostgaard, Klaus

PY - 2010/1

Y1 - 2010/1

N2 - Various blood safety initiatives have ensured a historically low risk of infection transmission through blood transfusion. Although further prevention of infection transmission is possible through, for example, nucleic acid testing and future introduction of pathogen inactivation, such initiatives are very costly in relation to the benefit they offer. Although estimation of the cost-effectiveness requires detailed information about the survival of transfusion recipients, previous cost-effectiveness analyses have relied on incorrect survival assumptions.

AB - Various blood safety initiatives have ensured a historically low risk of infection transmission through blood transfusion. Although further prevention of infection transmission is possible through, for example, nucleic acid testing and future introduction of pathogen inactivation, such initiatives are very costly in relation to the benefit they offer. Although estimation of the cost-effectiveness requires detailed information about the survival of transfusion recipients, previous cost-effectiveness analyses have relied on incorrect survival assumptions.

KW - Blood Banks

KW - Blood Transfusion

KW - Cost-Benefit Analysis

KW - Follow-Up Studies

KW - Humans

KW - Infection

KW - Infection Control

KW - Quality of Health Care

KW - Quality-Adjusted Life Years

KW - Risk Factors

KW - Scandinavia

KW - Survival Analysis

U2 - 10.1111/j.1537-2995.2009.02374.x

DO - 10.1111/j.1537-2995.2009.02374.x

M3 - Journal article

C2 - 19761551

VL - 50

SP - 240

EP - 242

JO - Transfusion

JF - Transfusion

SN - 0041-1132

IS - 1

ER -

ID: 32340624